Additionally, the CXCL12-CXCR4 axis plays a pivotal role in AML progression and drug resistance, with studies indicating that disruption of this axis can enhance the efficacy of targeted therapies [44, 45]. The gene discussed is CXCL12; the disease is acute myeloid leukemia.